Floatz logo

S-Ketamine

Obsessive-Compulsive Disorder

Mark NiciuActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Obsessive-Compulsive Disorder cohort.

Asset / SponsorPhaseRating
FLUOXETINE
Massachusetts General Hospital
Phase 4BB
Cipralex
BeerYaakov Mental Health Center
Phase 4BB
Sertraline
Yang I. Pachankis, PhD
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Uppsala University Hospital
Phase 2CCC
Clomipramine
National Center for Research Resources (NCRR)
Phase 2CCC

View all 10 →

Same molecule, other indications

S-Ketamine is also rated in:

depressive disorderDormant
A
Indicative ·
81 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
76 / 100
View asset →
depressive disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →